University of Cambridge,
(United Kingdom of Great Britain & Northern Ireland)
Risk Factors and Prevention
Coronary Artery Disease Chronic, Interventional Cardiology, Research Methodology
Brian is a cardiologist and genetic epidemiologist who was educated and trained at Yale, Harvard, Oxford and Cambridge Universities. He is currently Professor / Director of Research in Translational Therapeutics, and Executive Director of the Centre for Naturally Randomized Trials at the University of Cambridge, UK; and Professor of Cardiovascular Medicine at the University of Milan, Italy. His previous posts included Chief of Cardiology at Wayne State University School of Medicine in the US; Chief Medical and Scientific Officer for a public-private collaboration in Beijing; and CEO of a biotechnology company. His research focuses on using Mendelian randomization to design ‘naturally randomized trials’ to generate randomized evidence that can be used to improve the drug discovery and development process; inform the optimal design of randomized trials; fill evidence gaps when a randomized trial is not possible or practical; and define the practice of precision cardiovascular medicine.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease